Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation (SPICE-AF)
Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation (SPICE-AF)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Age 18-80 years
- Symptomatic paroxysmal or persistent AF eligible for first-time catheter ablation
- Body mass index ≥30 kg/m or body mass index ≥28 kg/m plus ≥1 weight-related comorbidity
- No prior treatment with glucacon-like peptide-1 receptor agonists
Exclusion criteria:
- Current use of glucacon-like peptide-1 receptor agonists or dipeptidyl peptidase 4 inhibitors or use within the last 90 days prior to screening
- Current antiobesity medication use or use within the last 90 days prior to screening
- A self-reported change in body weight of >5 kg within 30 days before screening
- History of bariatric surgery
- History of diabetes mellitus
- Hospitalization for unstable angina, or transient ischemic attack <30 days prior to screening
- Pulmonary embolism <90 days before screening
- Myocardial infarction, or stroke <90 days prior to screening
- Uncontrolled thyroid disease: thyroid-stimulating hormone >10.0 mIU/L or <0.4 mIU/L at screening
- Active malignancy
- Acute pancreatitis <180 days before screening
- History or presence of chronic pancreatitis
- Chronic kidney disease with creatinine clearance <30 mL/min
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- Chronic inflammatory conditions requiring immunosuppression and/or on glucocorticoids
- Pregnancy, breast-feeding or planning pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Catheter ablation for atrial fibrillation plus semaglutide
Catheter ablation for atrial fibrillation plus semaglutide (up to 2.4 mg weekly)
|
Catheter ablation for AF plus semaglutide (up to 2.4 mg weekly)
|
|
No Intervention: Catheter ablation for atrial fibrillation and no glucacon-like peptide-1 receptor therapy
Catheter ablation for atrial fibrillation and no glucacon-like peptide-1 receptor therapy (standard therapy)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Freedom from atrial arrhythmia (AF/atrial flutter/atrial tachycardia >30 sec) at 12 months post-ablation (8-week-blanking period)
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SPICE_AF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.